Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' Net Income towards Common Stockholders fell 1845.53% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 7314.91%. This contributed to the annual value of $275.2 million for FY2024, which is 44853.78% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$39.3 million for Q3 2025, which was down 1845.53% from -$34.8 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Net Income towards Common Stockholders peaked at $207.3 million during Q1 2024, and registered a low of -$41.0 million during Q2 2022.
  • Its 5-year average for Net Income towards Common Stockholders is -$7.5 million, with a median of -$33.2 million in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 33545.02% in 2021, then soared by 71479.61% in 2024.
  • Protagonist Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$37.2 million in 2021, then grew by 7.77% to -$34.3 million in 2022, then soared by 179.78% to $27.3 million in 2023, then skyrocketed by 381.7% to $131.7 million in 2024, then tumbled by 129.88% to -$39.3 million in 2025.
  • Its last three reported values are -$39.3 million in Q3 2025, -$34.8 million for Q2 2025, and -$11.7 million during Q1 2025.